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Haematological-oncologists in each of France, Germany, Italy, Spain and the UK, 
actively managing patients with Multiple Myeloma, were asked to complete patient 
record forms (PRF) prospectively for the next eight patients who consulted their 
clinic. In addition to clinical considerations, prescribers were asked to record the 
impact of administrative controls on their prescribing decisions as well as being 
asked attitudinal and perceptual information on the influence of payer recom-
mendations. Results: We observed national variation of the influence of payers 
on prescribing decisions. Administrative controls were cited as influencing more 
than 70% of prescribing decisions in all markets except Germany, where the figure 
was 50%. Inclusion on formulary was a strong driver of prescriber decisions about 
therapy, cited as a driver in the majority of individual decision in all markets except 
Germany. We also observed that prescribers reported that they would have selected 
an alternative treatment in around 1 in 8 patients, had administrative controls not 
been in place. Germany was the exception, where this figure is closer to 1 in 20 
individual prescribing decisions. ConClusions: This research demonstrates that 
prescribers’ behavior is strongly influenced by administrative controls to which 
payers contribute, and that there are differences between Germany and the other 
4 markets investigated. Further research will establish whether differences reflect 
actual differences in the nature and impact of controls, or simply greater alignment 
between prescribers’ and payers’ objectives or opinions in Germany. This has the 
potential to inform discussions between prescribers and payers about rational use 
of medicines and patients’ access to medicines.
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objeCtives: Tiered pricing, also referred to as differential pricing or equitable 
pricing, involves adjusting drug prices to the purchasing power of consumers in 
different geographical or socio-economic segments. Traditionally, tiered pricing 
strategies have aimed to improve access to medicines in the developing world. 
There has been increasing interest from manufacturers and payers in employing 
such strategies for oncology agents, but improved patient access and commercial 
success has been variable. This research aims to understand the challenges and 
opportunities associated with implementing tiered pricing for oncology agents and 
the factors that may contribute to a successful strategy. Methods: Systematically 
analyse a set of case studies in order to clearly identify current practice and trends 
in tiered pricing strategies for cancer drugs in key emerging markets. Evaluate vari-
ous strategies based on publically available information and identify drivers for 
improved patient access and commercial success. Results: Emerging markets 
represent a complex environment and a number of challenges such as physical 
and informational arbitrage impact a differential pricing strategy. Strategies driven 
by short-term profitability objectives have usually failed and those that have not 
addressed the inefficient distribution channels in emerging markets have also strug-
gled to gain traction. Additionally, a poor knowledge of demand elasticity has often 
limited impact. ConClusions: Tiered pricing strategies represent a powerful tool 
for improving patient access to cancer drugs in emerging markets. Every tiered 
pricing strategy needs to be tailored to each product and market/ segment. A clear 
understanding of the objectives driving the strategy, the potential pricing tools 
applicable in a market, the distribution channels and methods to mitigate risk are 
key to improving patient access and supporting commercial success.
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objeCtives: Oncology medicines reimbursed in France have a fixed price whereas 
the benefits vary across patient groups. Pricing models aligned to the benefit for 
patients open an interesting concept, but they need to be supported by reliable and 
standardised metrics aligned with heath authorities ‘expectation. The Personalised 
Reimbursement Models (PRM) pilots aim to establish an infrastructure validated by 
the National Data Privacy Committee to collect existing data of metastatic breast 
cancer patients (mBC) taking trastuzumab and leverage preliminary analytics to 
evaluate the relevance of this approach. Methods: mBC patients at 14 pilots cen-
tres recorded in the Electronic Pharmacy Record (EPR) system with at least one 
trastuzumab claim between January 2011 to October 2014 that were not enrolled in 
a clinical trial were selected. Data related to demographics, disease description, drug 
usage and clinical outcomes were collected in the EPR. These data were controlled, 
cleaned and centralised in an anonymous and secure way through an accredited 
hosting provider. Results: 510 mBC patients taking trastuzumab were identified. 
21 of the 30 target variables were available in the EPR with a mean of 3.5% percent of 
missing data and results that were consistent with literature. Unavailable variables 
have been identified in other data sources within centres or could be added to the 
EPR by updating and enhancing the health information systems. The recruitment of 
around 100 additional centres began in January 2015 following a sampling method 
designed to ensure the representativeness of clinical practice. ConClusions: Pilot 
study has validated technical and legal feasibility of the PRM infrastructure imple-
mentation and the quality of the outputs. Over time, PRM will deliver robust and 
standardised real world evidence that could be used to implement models that will 
support more flexible pricing strategies and help ensure patient access to innovative 
treatments delivered in different indications.
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to identify patients diagnosed with ovarian cancer and were taking treatment from 
January 2001 to December 2013 were included in the study. All patients were ≥ 18 
years of age and continuously enrolled in the same health plan at least for a year. 
Descriptive statistics and chi-square tests were performed on the data. Results: 
There were a total of 2,562 patients that met the study inclusion criteria. There 
were 1,718 (67.10%) patients < 65 years of age (adult) and 844 (32.90%) ≥ 65 years of 
age (geriatric). There was a significant difference (p< 0.05) between the mean ages 
of two groups (52.48±9.76 vs 73.08±6.62 years). The mean length of stay of adult 
patients was lower than (p< 0.05) geriatric patients (1.23±1.57 vs 1.45±2.67 days). 
There were more patients in adult group in the East (23.5% vs 21.0%) and MidWest 
(30.3% vs 27.6%) regions but no significant difference was found (p> 0.05). On aver-
age, patients were continuously enrolled in the same health plan for 62.00±37.03 
vs 66.64±35.21 months and submitted 567.10±574.49 vs 740.58±629.71 claims with 
a significant difference (p< 0.05) between the two groups. Patients on average were 
charged by the provider $533.62±2232.26 vs $492.09±2123.24 for their ovarian can-
cer treatment (p< 0.05) during the study period. However, the actual paid amount 
by the health plan was $225.25±1215.97 vs $136.79±962.99 with a significant dif-
ference between the groups (p< 0.05). ConClusions: The majority of the patients 
were < 65 years of age and were paid higher amount by the health plan for the 
treatment of ovarian cancer.
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objeCtives: The objective of this study is to assess the characteristics and health 
care resource utilization of patients diagnosed with prostate cancer. Methods: A 
large US administrative retrospective claims database was used to identify patients 
diagnosed with prostate cancer and were taking treatment in the USA from January 
2001 to December 2013 were included in the study. All patients were ≥ 18 years of 
age and continuously enrolled in the same health plan at least for a year. Descriptive 
statistics and chi-square tests were performed on the data. Results: There were a 
total of 19,279 patients that met the study inclusion criteria. Of these, 6,359 (33.0%) 
patients were < 65 years of age (adult) and 12,920 (67.0%) ≥ 65 years of age (geriat-
ric). There was a significant difference (p< 0.05) in the mean ages of two groups 
(59.02±4.99 vs 74.55±6.55 years). There were more patients in adult group in the 
MidWest (28.5% vs 23.6%) and South (38.3% vs 36.4%) regions with a significant 
difference between the groups (p< 0.05). On average, patients were continuously 
enrolled in the same health plan for 65.37±35.91 vs 65.80±32.84 months (p> 0.05) and 
submitted 366.85±381.92 vs 492.37±431.42 claims during the study period (p< 0.05). 
Patients on average were charged by the provider $763.84±3003.48 vs $595.56±2207.71, 
the allowed amount by the health plan was $343.75±1496.33 vs $270.81±1380.54 and 
the actual paid amount by the health plan was $309.67±1294.90 vs $165.08±768.48 
with a significant difference between the groups (p< 0.05). ConClusions: The 
majority of the patients were geriatric. On average, geriatric patients were charged 
less by the provider and actual paid amount by the health plan was less compared 
to adult patients for the treatment of prostate cancer.
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objeCtives: The objective of this study is to assess the characteristics and health 
care resource utilization of patients diagnosed with malignant neoplasm of rec-
tum. Methods: A large US administrative retrospective claims database was used 
to identify patients diagnosed with malignant neoplasm of rectum and were tak-
ing treatment in the USA from January 2001 to December 2013 were included in 
the study. All patients were ≥ 18 years of age and continuously enrolled in the 
same health plan at least for a year. Descriptive statistics and chi-square tests 
were performed on the data. Results: There were a total of 2,461 patients that 
met the study inclusion criteria. Of these, 1,695 (68.87%) were < 65 years of age 
(adult) and 766 (31.13%) were ≥ 65 years of age (geriatric). There was no difference 
(p> 0.05) in the distribution of males (57.2% vs 57.0%) and a significant difference 
(p< 0.01) between the mean ages of two groups (53.49±7.50 vs 72.73±5.26 years) was 
found. The mean length of stay between the groups (1.96±4.37 vs 1.96±4.56 days) 
was almost same. There were more patients in adult group in the East (31.3% vs 
22.7%) and South (38.3% vs 37.3%) regions with a significant difference (p< 0.05) 
between the groups. On average, patients were continuously enrolled in the same 
health plan for 63.50±36.74 vs 64.43±32.40 months and submitted 640.33±580.25 
vs 680.26±598.82 claims with no significant difference (p> 0.05) between the two 
groups. Patients on average were charged by the provider $611.69±2771.24 vs 
$639.36±3554.90 (p> 0.05), allowed amount by the health plan was $284.71±1515.83 
vs $287.31±1996.25 (p> 0.05) and the actual paid amount by the health plan was 
$268.84±1490.76 vs $145.21±1068.87 (p< 0.05). ConClusions: The majority of the 
patients were adult and health plans paid higher amount for these patient groups 
compared to geriatric patients for the treatment of malignant neoplasms of rectum.
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iNTerNaTiONal differeNCes iN The rOle Of Payer aNd admiNisTraTive 
CONTrOls iN PresCriBiNg deCisiONs
Silvey M, Rider A, Wellam HW, Piercy J
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objeCtives: To assess the extent to which prescribing decisions are influenced by 
payer implemented controls. Methods: Data were drawn from the Adelphi Disease 
Specific Programme (DSP) in Multiple Myeloma conducted in Q1 2015. DSPs are cross 
sectional surveys of physicians and their consulting patients. Fifty Haematologists/
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innovation provides opportunities for immediate benefit, including survival until 
the next therapy is available, and may uncover new clinical pathways with signifi-
cant cumulative benefit. Recognition of this “option value” for future health and 
research advances is needed.
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uNiTed sTaTes (us)
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Ipsos Healthcare, Washington, DC, USA
objeCtives: The 2014 American Society of Clinical Oncology (ASCO) payment 
reform proposal includes value-based adjustments based on performance on qual-
ity, use of/adherence to pathways, and utilization of other healthcare resources. 
The objective of this analysis was to assess current use of QOC metrics in US can-
cer care. Methods: Medical-oncologists and hematologist/oncologists across the 
US, practicing for at least 2yrs and managing at least 20 patients, were randomly 
sampled to participate in a cross-sectional survey via a panel. Results: 231 phy-
sicians participated (87% physicians, 13% medical directors; 67.5% hematologist/
oncologists, 32.5% medical-oncologists; median age group 40-49yrs). Mean practice 
duration:15yrs; 53% practice in an academic/community/Veteran’s facility and 47% 
in group/solo private practice; 41% are part of an Accountable Care Organization 
(ACO); 89% use electronic health records (EHR). The most common QOC metric 
used was patient satisfaction scores (60%), followed by Quality Oncology Practice 
Initiatives:43%, adherence to clinical pathways:36%, Physician Quality Reporting 
System:35%, Commission on Cancer standards:24%, other:11%, and CancerLinQ:3%; 
None/not-sure:13%. Overall, 81% stated that their organization’s quality measure-
ment and tracking procedures were “somewhat/highly effective” in terms of improv-
ing quality of care, outcomes, and cost-savings. Average of 76% of cancer patients 
were reported to generally adhere to NCCN guidelines/pathways in the organization; 
84% were reported to have documented clinical/pathologic staging prior to initia-
tion of treatment (87% among non-ACO physicians, 80% among ACO physicians; 
p= 0.04). Use of at least one quality metric was more common among physicians 
participating in an ACO (93% vs. 83%; p= 0.04). Use of patient satisfaction scores was 
more common among physicians using EHR (62% vs. 42%; p= 0.048). ConClusions: 
Standard QOC metrics for cancer care appear to be underutilized and appear to vary 
based on an affiliation with an ACO or use of EHR. Impact of observed patterns on 
patient care delivery/outcomes warrants scrutiny.
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objeCtives: The Prostate Cancer Registry (NCT02236637) is an international, pro-
spective, observational study of mCRPC patients. One purpose is to evaluate the 
impact of mCRPC treatment on MRU in routine practice. Methods: Patients were 
enrolled upon initiation of mCRPC treatment or during surveillance in > 150 centres 
across 16 countries. Baseline MRU was collected for 1 year before enrolment, and 
then prospectively at 3-month intervals. Baseline data were converted to a 3-month 
average to align with prospectively-collected data. We analyzed the MRU parameters 
of outpatient visits and hospitalization days at three months after treatment ini-
tiation. Results: We report data from 505 patients who were post-chemotherapy 
(n= 209) or chemotherapy-naïve (n= 296), with mean age 71.5 years and mean time 
since diagnosis 5.7 years. At baseline, MRU was greater for post-chemotherapy vs 
chemotherapy-naïve patients; mean total outpatient visits: 4.8 (range: 0-18) vs 2.5 
(range: 0-13) and mean total hospitalization days: 1.1 (range: 0-15) vs 0.6 (range: 0-8). 
For patients initiating new post-chemotherapy mCRPC treatment during follow-up 
(164/505 patients; 33%), MRU was analyzed by first treatment: abiraterone (n= 74), 
enzalutamide (n= 46), cabazitaxel (n= 44). In the first three months, mean (SD) and 
median [range] number of outpatient visits among patients with evaluable data 
were 4.2 (2.96) and 4.0 [0-13] for abiraterone (n= 51 patients with evaluable data); 
4.3 (2.94) and 4.2 [0-14] for enzalutamide (n= 32); and 7.6 (5.15) and 6.5 [1-30] for 
cabazitaxel (n= 38). During the same period, the mean (SD) number of hospitalization 
days was 2.6 (8.47) for abiraterone (n= 55); 2.2 (5.51) for enzalutamide (n= 33); and 1.5 
(3.94) for cabazitaxel (n= 40). Median number of hospitalization days was zero across 
treatments indicating < 50% of patients required hospitalization. ConClusions: 
As these real-world data mature, the impact of different routine mCRPC treatments 
on MRU across multiple countries, medical disciplines and clinical settings may 
provide valuable insights to benefit patient care.
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objeCtives: Radiation oncology is a key therapeutic strategy in cancer care. In 
order to assess the gap between the actual use of this therapy and evidence-based 
indications, we compare the number of new cancer patients that will require at 
least one course of radiotherapy in 24 European countries to its actual use, and 
project the results to 2020. Methods: Incidence from each cancer type estimated 
by the European Cancer Observatory for 2012 was used in combination with the 
stages at diagnosis from five population-based cancer registries. Projections of can-
cer incidence to 2020 were also used. These data were applied to evidence-based 
decision trees for all tumors to calculate the Optimal Utilization Proportion (OUP). 
Data on actual use come from national radiotherapy societies. Results: Average 
OUP in European countries was 51% with a range from 47% (Russian Federation) 
to 53% (Belgium). The median actual use of radiotherapy was 69% of the OUP in 
the 24 countries analyzed. Only four countries showed an actual use higher than 
80% of the OUP. Projection of cancer incidence to 2020 showed a 10.1% increase in 
the number of candidates for radiotherapy compared to 2012, with most western 
European countries with increases between 10 and 15%. In absolute number of 
patients, this means an increase of 154294 for the EU 27 countries in this 8 years 
period. ConClusions: The gap between optimal and actual use of radiotherapy 
poses a challenge to policy makers when planning future therapeutic resources. 
In order to reduce the gap, the focus on accessibility, reimbursement policies and 
multidisciplinary team clinical decision-making is mandatory. Also, there is a need 
to set reasonable targets that help pave the way to optimal use, keeping in mind the 
challenges which might make the OUP difficult to achieve.
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objeCtives: Most policy decisions have a spatial component that can be integrated 
in formal decision making using geographic information systems (GIS) and multi-
criteria decision analysis (MCDA). However, GIS-MCDA is not commonly used in 
a health (economic) policy setting. The aim of this study is to introduce the spa-
tial component of healthcare policy decisions and to illustrate an application of 
GIS-MCDA using a case on comparing lung cancer screening versus smoking preven-
tion programs in the Netherlands. Methods: Demographic data and data concern-
ing the distribution of persons at-risk of developing lung cancer were obtained from 
the Statistics Netherlands institute and aggregated per public health service (GGD) 
region. Effectiveness and costs data were obtained from literature and assumed to 
differ across population subgroups. The simple multi-attribute rating technique 
(SMART) method of MCDA was used. The GIS-MCDA model was built using ArcGIS 
software. Results: The effectiveness of either a screening or a prevention pro-
gram differed substantially across the GGD regions, reflecting differences in age 
distribution and percentage of young and old smokers. Considering the adjacency 
of regions, a different policy may be optimal for the north-east region (preven-
tion) and the south-west region (screening), but this may raise ethical questions of 
equity. Sensitivity analyses reveal that the decision is sensitive to the percentage 
of older smokers in a region and the relative cost of screening versus prevention. 
Limitations of the study are that the costs of implementation are not taken into 
account, that the time horizon was limited and that a non-exhaustive set of criteria 
was used. ConClusions: GIS-MCDA can be a useful method to gain insight into 
the spatial component of healthcare policy decisions. Further research is required 
into including elicited preference data into the model, into including uncertainty 
in model parameters more formally and into selecting sets of alternatives (e.g. 
screening locations) based on a GIS-MCDA analysis.
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objeCtives: Breakthrough innovation in oncology is commonly considered to be 
a substantial increase in overall survival (OS) above specific thresholds. However, 
this growing emphasis on significant OS gain, undervalues new products and may 
not capture aspects of treatment that are important to patients, including qual-
ity of life, delayed progression or improvements in side-effect profiles. We argue 
that progressive innovation in clinical and non-clinical domains needs to be con-
sidered and valued in regulatory and health technology assessment (HTA) deci-
sions. Methods: Definitions of innovation used in regulatory, HTA, and industry 
were reviewed in the academic and gray literature and current/proposed OS thresh-
olds applied to therapies in colorectal cancer (CRC) and non-small cell lung cancer 
(NSCLC). Results: Regulators and HTA agencies do not provide clear consistent 
definitions of innovation; however, the magnitude of OS benefit is a consistent key 
aspect from both policy (e.g., England’s Cancer Drugs Fund) and clinical perspec-
tives (e.g., ASCO). Emphasis is on “clinically meaningful” change expressed as mini-
mum thresholds: OS gain > 2.5months; HR > 0.8; PFS gain > 3 months, HR > 0.5.. Only 
one of six CRC drugs approved since 2000 met these thresholds (ASCO; Ellis et al. 
2014) although survival has doubled in that time. No NSCLC products have met the 
threshold since 2005 whereas survival in first line treatment for advanced disease 
has doubled. ConClusions: Innovation should be judged in relation to the value 
provided to patients and health systems, and should not be restricted to one-time 
large survival gains. Smaller sequential clinical gains and improved quality of life, 
safety, convenience, and system efficiency should also be considered. Progressive 
